Tzikos Georgios, Menni Alexandra-Eleftheria, Krokou Despoina, Vouchara Angeliki, Doutsini Soultana, Karlafti Eleni, Karakatsanis Anestis, Ioannidis Aristeidis, Panidis Stavros, Papavramidis Theodosios, Michalopoulos Antonios, Paramythiotis Daniel
1st Propedeutic Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Emergency Department, AHEPA University General Hospital of Thessaloniki, 54636 Thessaloniki, Greece.
J Pers Med. 2023 Aug 13;13(8):1254. doi: 10.3390/jpm13081254.
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal neoplasms of the gastrointestinal tract. They have variable clinical presentation, prognosis, and molecular characteristics. Here, we present the results of our retrospective study including patients operated on for GIST during the last decade.
All the patients who underwent GIST resection during the decade 2008-2018 were included in the study. The diagnosis was based on the pathology report. All the data were collected and analyzed statistically using the Statistical Package for Social Science v25.0. Finally, after having applied the proper search terms, a comprehensive review of articles published in the Medline database was held.
Thirty-two patients (sixteen women) were included in the study with a mean age of 69.6 years old (SD = 13.9). Twenty-one patients had a GIST in the stomach, eight in the small intestine, and three had an extra GIST. Of the 29 patients contacted, 21 were alive with a mean survival time of 74.3 months (SD = 49.6 months, min: 3.0 months, max: 161.0 months), whereas eight patients passed away. Finally, 13 patients were treated with tyrosine kinase inhibitors (TKIs) of whom only one died, while 9 patients passed away from those treated with surgery alone ( = 0.031).
Our results were in concordance with the existing data in the literature. GISTs require patient-based therapeutical management depending on the histology of the tumors. Gastric tumors present a better prognosis than those localized in the intestine, while the use of TKIs has led to an improvement in patient survival rate.
胃肠道间质瘤（GISTs）是胃肠道最常见的间叶性肿瘤。它们具有不同的临床表现、预后和分子特征。在此，我们展示了我们的回顾性研究结果，该研究纳入了过去十年接受GIST手术的患者。
纳入2008年至2018年这十年间接受GIST切除的所有患者。诊断基于病理报告。所有数据均使用社会科学统计软件包v25.0进行收集和统计分析。最后，在应用适当的检索词后，对Medline数据库中发表的文章进行了全面综述。
该研究纳入了32例患者（16名女性），平均年龄为69.6岁（标准差=13.9）。21例患者胃部有GIST，8例在小肠，3例有额外的GIST。在联系的29例患者中，21例存活，平均生存时间为74.3个月（标准差=49.6个月，最小值：3.0个月，最大值：161.0个月），而8例患者去世。最后，13例患者接受了酪氨酸激酶抑制剂（TKIs）治疗，其中仅1例死亡，而9例仅接受手术治疗的患者去世（P=0.031）。
我们的结果与文献中的现有数据一致。GISTs需要根据肿瘤的组织学进行基于患者的治疗管理。胃部肿瘤的预后比肠道肿瘤更好，而TKIs的使用提高了患者的生存率。
